We are live on
!
Find out more
BioCryst Pharmaceuticals
BCRX
BCRX
301 hedge funds and large institutions have $2.37B invested in BioCryst Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 114 increasing their positions, 76 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
134% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $6.09M
83% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 41
50% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 76
43% more capital invested
Capital invested by funds: $1.66B → $2.37B (+$713M)
10% more funds holding
Funds holding: 273 → 301 (+28)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.56% less ownership
Funds ownership: 100.86% → 99.31% (-1.6%)
Holders
301
Holders Change
+28
Holders Change %
+10.26%
% of All Funds
3.71%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
75
Increased
114
Reduced
76
Closed
41
Calls
$14.2M
Puts
$6.09M
Net Calls
+$8.13M
Net Calls Change
+$3.86M
Top Buyers
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$85.6M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$37.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$33.2M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$32.1M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$31.1M |
Top Sellers
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$28.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$22M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$16.9M |
| 4 |
Squarepoint
New York
|
-$12.6M |
| 5 |
Renaissance Technologies
New York
|
-$10.5M |
